Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs 10X Genomics Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.76, while 10X Genomics Inc trades at $67.74 (market cap $8.77B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | TXG | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $81.00 | $67.29 |
52-Week Low | $11.55 | $11.34 |
Market Cap | — | $8.77B |
Enterprise Value | — | $8.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.49, down 3.55% over 24 hours, with a bullish technical signal driven by moving averages. The ETF shows a pattern of weekly dividend distributions, but financial ratios like P/E and P/S are unavailable. Recent news highlights high distribution yields but also significant NAV erosion and tax implications for investors.
The outlook is mixed: high income potential from distributions appeals to income-focused investors, but risks include capital depreciation and structural flaws in the fund's strategy. Investors should weigh the trade-off between yield and principal retention carefully.
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
